Abstract
Adult acute myeloid leukemia (AML) patients who are considered eligible for intensive chemotherapy are treated with regimens that include anthracyclines and cytarabine (AraC), also known as 7+3. Clinical and genetic abnormalities are used to indicate the best therapy strategy, and more recently, are essential in selecting patients who will benefit from targeted therapies (e.g., FLT3 inhib…